2021
Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment
Paltiel AD, Zheng A, Schwartz JL. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. Annals Of Internal Medicine 2021, 174: m20-7866. PMID: 33395345, PMCID: PMC7787166, DOI: 10.7326/m20-7866.Peer-Reviewed Original Research
2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2018
Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement
Smith KC, Paltiel AD, Yang HY, Collins JE, Katz JN, Losina E. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement. Osteoarthritis And Cartilage 2018, 26: 1495-1505. PMID: 30092263, PMCID: PMC6202236, DOI: 10.1016/j.joca.2018.07.014.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesFinancial incentivesOne-way sensitivity analysesDeterministic sensitivity analysesCost-effectiveness ratioSensitivity analysisCost-effectiveness outcomesOsteoarthritis Policy ModelEfficacy of THCKnee replacement recipientsPolicy modelLife yearsTelephonic health coachingQALYHealthcare perspective
2011
The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance
2007
Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries
Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 78-90. PMID: 17589368, PMCID: PMC3570247, DOI: 10.1097/qai.0b013e31812506fd.Peer-Reviewed Original ResearchConceptsEffective HIV vaccineHIV prevalenceHIV vaccineCondom useHIV infectionRisk behaviorsFuture HIV prevalenceTotal HIV infectionsHeterosexual HIV epidemicSuccessful vaccination campaignsRisk behavior changeVaccination statusMiddle-income countriesVaccinated individualsVaccination coverageDisease stageVaccine efficacyHIV epidemicVaccination scenariosVaccination campaignHigh riskAdult populationVaccinePrevalenceInfection
2006
The Survival Benefits of AIDS Treatment in the United States
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The Survival Benefits of AIDS Treatment in the United States. The Journal Of Infectious Diseases 2006, 194: 11-19. PMID: 16741877, DOI: 10.1086/505147.Peer-Reviewed Original ResearchConceptsSurvival benefitAntiretroviral therapyPotent combination antiretroviral therapyPneumocystis jiroveci pneumonia prophylaxisHIV disease treatmentImmunodeficiency syndrome careOpportunistic infection prophylaxisTotal survival benefitUntreated HIV diseaseCombination antiretroviral therapyEffective antiretroviral therapyPrevention of motherAbsence of treatmentYears of lifePneumonia prophylaxisChild transmissionInfant infectionAdult patientsHIV diseaseInfection prophylaxisDisease careNew diagnosisAIDS treatmentProphylaxisSurvival increase
2005
Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients
Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy 2005, 10: 41-52. PMID: 15751762, DOI: 10.1177/135965350501000102.Peer-Reviewed Original ResearchConceptsCD4 cell countQuality-adjusted life yearsHIV RNA monitoringAntiretroviral therapy initiationIncremental CE ratioCell countAntiretroviral therapyTherapy initiationTreatment thresholdCD4 cell count thresholdCD4 cells/mm3Initial clinical presentationCells/mm3Log10 copies/Incremental clinical benefitLife expectancyQuality-adjusted life expectancyHIV simulation modelHypothetical clinical settingsMore frequent monitoringCost-effectiveness analysisCell count thresholdAntiretroviral initiationVirological predictorsHIV RNA
1991
Modeling zidovudine therapy: a cost-effectiveness analysis.
Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 795-804. PMID: 1906934.Peer-Reviewed Original Research